CompletedNCT04292964Updated Mar 17, 2020

Prognostic Factors of Patients With COVID-19

An observational study in SARS-CoV-2 and Outcome, Fatal, sponsored by Chongqing Medical University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-17.

Sponsored by Chongqing Medical University · Observational

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 201
Ages: 18 Years and older
Sex: All

Study summary

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Conditions studied

SARS-CoV-2
Outcome, Fatal

In context

Lead sponsor

Chongqing Medical University is the lead sponsor of 78 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with COVID-19

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult aged >=18years old;
Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.
Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.

Exclusion criteria

Exclusion Criteria:

Near-death state (expected survival time less than 24 hours);
Malignant tumor;
Pregnancy or puerperium women;
Patients who refused to participant.

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 201 participants (actual)
Patient registry: No

What researchers measure

Primary outcomes

all-cause mortality
Time frame: 30 days

Secondary outcomes

all-cause mortality
Time frame: 15 days
Severe state
Criteria for severe or critical ill conditions: Respiratory rate \>=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.
Time frame: 15 days

Study locations

1 site

The First Affiliated Hospital of Chongqing Medical University
Chongqing, China

References and documents

Publications

Wen XS, Jiang D, Gao L, Zhou JZ, Xiao J, Cheng XC, He B, Chen Y, Lei P, Tan XW, Qin S, Zhang DY. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis. 2021 Jan 12;21(1):57. doi: 10.1186/s12879-020-05741-w. PubMed 33435865 ↗
Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ, Zhang DY. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w. PubMed 32293449 ↗

Individual participant data

Plan to share: No

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Mar 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered: Mar 1, 2020
First posted: Mar 3, 2020
StartActual: Mar 1, 2020
Primary completionActual: Mar 13, 2020
CompletionActual: Mar 13, 2020
Last update: Mar 17, 2020

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Mar 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04292964
Lead sponsor: Chongqing Medical University
Responsible party: Dongying Zhang (Clinical Professor, Chongqing Medical University) — Principal investigator
First posted: Mar 3, 2020
Start date: Mar 1, 2020
Primary completion: Mar 13, 2020
Completion: Mar 13, 2020
Last update: Mar 17, 2020

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Chongqing Medical University

Start the discussion